Cytokinetics Logo
US23282W6057
A1W1KK
CYTK

Cytokinetics

Previsioni

Il prezzo obiettivo medio degli analisti è 97,64 € (+110,89%). La mediana è 102,07 € (+120,45%).

Acquista
  34
Mantieni
  1
Vendi
  0

Discussioni nella community

Non ci sono ancora discussioni su questo asset.

Avvia discussione

  • Cytokinetics added to Polaris portfolio after Myqorzo seen superior to Camzyos

    Polaris Capital Management added Cytokinetics to its Q2 2026 Global Equity Strategy, citing FDA approval of Myqorzo for hypertrophic cardiomyopathy and its perceived superiority to Bristol Myers Squibb's Camzyos in symptom relief and dosing simplicity. Cytokinetics closed at $67.59 on Sept. 22, 2026, with a market cap of $9.4 billion, a 52-week range of $47.22–$88.31 and a one-month decline of 14.66% versus a 52-week gain of 39.97%. Polaris noted the company amid strong quarter-wide gains driven by AI holdings, and hedge fund ownership of Cytokinetics rose to 78 portfolios at quarter end. » Altro su finance.yahoo.com


  • Cytokinetics bets on MYQORZO expansion in HCM and prepares NHCM approval

    At the Citigroup conference, Cytokinetics reported a better-than-expected launch for MYQORZO in obstructive HCM, capturing a 40% share of new prescriptions by the end of Q2 2026. ACACIA-HCM phase 3 data showed superiority in non-obstructive HCM (NHCM) and support a planned regulatory filing; the company estimates NHCM could represent about 50% of the HCM market. There was a slight imbalance of serious heart-failure events in ACACIA, which the company views as manageable and plans to publish additional safety data. Cytokinetics plans to increase SG&A spending to support NHCM expansion and its European roll‑out (Germany launched, UK Q4 2026, other markets in 2027) and is advancing the COMET-HF confirmatory study of Omecamtiv Mecarbil in parallel. » Altro su de.investing.com


  • Cytokinetics beats Q2 2026 estimates thanks to launch of MYQORZO

    Cytokinetics reported a loss of $1.50 per share for Q2 2026 on revenue of $28.6 million, well above the consensus estimate of $17.09 million. The driver was the launch of the heart drug MYQORZO, which generated net product revenues of $25.3 million and treated more than 1,500 patients by the end of the quarter. The company raised its 2026 spending expectations due to increased commercial investments and holds $1.7 billion in cash. Management emphasized continued market momentum but noted risks from high costs, reliance on MYQORZO and reimbursement uncertainties. » Altro su de.investing.com


  • MHRA grants Cytokinetics approval for Aficamten in the UK

    The MHRA has approved Cytokinetics’ Aficamten (MYQORZO) for the treatment of symptomatic obstructive hypertrophic cardiomyopathy in adult patients. NICE recommends use in England and Wales for patients in NYHA classes II–III as an add‑on to optimized standard therapy or as monotherapy when there are contraindications. The decision is based on the phase‑3 SEQUOIA‑HCM study, which showed a mean difference in peak oxygen uptake of 1.7 ml/kg/min (p < 0.001) versus placebo. Common adverse events included hypertension, palpitations, dizziness and systolic dysfunction; availability through the NHS is expected later this year. » Altro su de.investing.com


  • Cytokinetics gains momentum as Myqorzo commercial rollout expands

    Cytokinetics is transitioning from development to commercial stage following regulatory approvals for Myqorzo in the US, Europe and China, with early physician adoption and patient response supporting initial sales momentum. Positive trial readouts are expanding the drug's potential into related cardiac indications, while a differentiated mechanism and a pipeline of next-generation candidates could broaden its addressable market. Market interest and volume-supported price action indicate accumulation as investors reassess long-term growth and pricing power in a market with limited competition. » Altro su finance.yahoo.com

Dati finanziari

Nell'ultimo trimestre, Cytokinetics ha registrato ricavi pari a 41,99 Mln € e un utile netto di -167,8 Mln €

(EUR) settembre 2026
YoY
Ricavi 41,99 Mln 2445,01%
Utile lordo 40,03 Mln 2326,43%
Utile netto -167,8 Mln 35,68%
EBITDA -130,61 Mln 44,70%

Dati fondamentali

Metrica Valore
Capitalizzazione di mercato
6,52 Mld €
Numero di azioni
139,3 Mln
Massimo/minimo a 52 settimane
80,48 € - 46,52 €
Dividendi No
Beta
0,36
Rapporto P/E
-8,51
Rapporto PEG
-8,41
Rapporto P/B
-22,22
Rapporto P/S
63,10

Profilo aziendale

Cytokinetics, Incorporated, una società biofarmaceutica in fase avanzata di sviluppo, si concentra sulla scoperta, sviluppo e commercializzazione di attivatori e inibitori muscolari come potenziali trattamenti per malattie invalidanti. La società sviluppa candidati farmaci a piccola molecola progettati principalmente per influenzare la funzione muscolare e la contrattilità. I suoi candidati farmaci includono omecamtiv mecarbil, un nuovo attivatore della miosina cardiaca che si trova in sperimentazione clinica di Fase III su pazienti con insufficienza cardiaca; e reldesemtiv, un attivatore della troponina del muscolo scheletrico, che si trova in sperimentazione clinica di Fase III per il trattamento della sclerosi laterale amiotrofica e dell'atrofia muscolare spinale. La società sviluppa inoltre CK-136, un nuovo attivatore della troponina cardiaca che si trova in sperimentazione clinica di Fase I; aficamten, un nuovo inibitore della miosina cardiaca, che si trova in sperimentazione clinica di Fase III per il trattamento di pazienti con cardiomiopatia ipertrofica ostruttiva sintomatica; e CK-3772271, un inibitore della miosina cardiaca a piccola molecola che si trova in sperimentazione clinica di Fase I. Cytokinetics, Incorporated ha un'alleanza strategica con Astellas Pharma Inc. La società è stata costituita nel 1997 e ha sede a South San Francisco, California.

Nome
Cytokinetics
CEO
Robert I. Blum
Sede centrale South San Francisco, ca
Stati Uniti
Sito web
Settore
Materiali
Industria
Prodotti chimici
Quotazione in borsa
30/04/2004
Dipendenti 673

Simboli di borsa

Borsa Simbolo
NASDAQ
CYTK
Frankfurt
KK3A.F
Düsseldorf
KK3A.DU
SIX
KK3A.SW
München
KK3A.MU
🍪

Parqet  usa i cookie. Scopri di più